THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS

THE PLACE OF TOFACITINIB IN THE TREATMENT STRATEGY OF RHEUMATOID ARTHRITIS

Objective: to determine the efficiency and safety of therapy with tofacitinib (TOFA) in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) after insufficient previous therapy in real clinical practice.Subjects and methods. The investigation enrolled a total of 33 p...

Full description

Bibliographic Details
Main Authors:	V. I. Mazurov, E. A. Trofimov, R. R. Samigullina, I. Z. Gaidukova
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2018-05-01
Series:	Научно-практическая ревматология
Subjects:	tofacitinib rheumatoid arthritis targeted therapy biological therapy
Online Access:	https://rsp.mediar-press.net/rsp/article/view/2519

Similar Items

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

Co-Delivery of Loxoprofen and Tofacitinib by Photothermal Microneedles for Rheumatoid Arthritis Treatment
by: Yi Lu, et al.
Published: (2023-05-01)

Retention on tofacitinib therapy in patients with rheumatoid arthritis (real clinical practice data)
by: G. I. Gridneva, et al.
Published: (2022-12-01)

Efficacy of tofacitinib on rheumatoid arthritis: A retrospective single-center cohort study
by: Yuhui Qi, et al.
Published: (2023-09-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01)

Clinical significance of Janus kinase inhibitors in the therapy of rheumatoid arthritis: achievements and prospects
by: V. I. Mazurov, et al.
Published: (2019-10-01)

Effect of tofacitinib therapy on angiotensin converting enzyme activity in rheumatoid arthritis
by: Dorottya Kacsándi, et al.
Published: (2023-10-01)

Is Tofacitinib Effectiveness in Patients with Rheumatoid Arthritis Better After Conventional Than After Biological Therapy? – A Cohort Study in a Colombian Population
by: Santos-Moreno P, et al.
Published: (2022-07-01)

Seronegative cutaneous rheumatoid nodules with positive response to tofacitinib
by: Matthew Helm, MD, et al.
Published: (2024-08-01)

Tofacitinib is a modern solution to the problem of resistant rheumatoid arthritis
by: I. V. Menshikova, et al.
Published: (2019-05-01)

Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis
by: Paola Di Benedetto, et al.
Published: (2021-08-01)

An effective strategy with tofacitinib for the management of focal myositis with rheumatoid arthritis: a case report
by: Jing Pan, et al.
Published: (2024-12-01)

Treatment interruption of biological drugs and tofacitinib in rheumatoid arthritis: A systematic review of case reports
by: Astrid Wiens, et al.
Published: (2019-04-01)

Reactivation of latent tuberculosis infection following initiation of tofacitinib therapy for rheumatoid arthritis: A case report
by: Nishant Johri, et al.
Published: (2023-12-01)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Tofacitinib Decreases Autophagy of Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
by: M. Vomero, et al.
Published: (2022-03-01)

Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis
by: Zhan-Guo Li, et al.
Published: (2018-01-01)

Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6
by: Piero Ruscitti, et al.
Published: (2022-05-01)

Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis
by: Monika Czókolyová, et al.
Published: (2022-10-01)

Effectiveness and Predictors of Long-Term Treatment Response to Tofacitinib in Rheumatoid Arthritis Cohort: General Analysis and Focus on High-Cardiovascular-Risk Subgroup—A Multicenter Study
by: Marta Priora, et al.
Published: (2024-12-01)

Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
by: Boyce EG, et al.
Published: (2016-01-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy
by: M. Tasso, et al.
Published: (2022-12-01)

Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports
by: Tetsuo Kobayashi, et al.
Published: (2019-04-01)

ANALYSIS OF THE RESULTS OF TOFACITINIB THERAPY IN REAL CLINICAL PRACTICE ACCORDING TO THE ALL-RUSSIAN ARTHRITIS REGISTRY (OREL)
by: A. S. Avdeeva, et al.
Published: (2020-06-01)

Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
by: A. E. Karateev, et al.
Published: (2021-09-01)

A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
by: A. E. Karateev, et al.
Published: (2020-05-01)

Ultrasound response to tofacitinib in patients with rheumatoid arthritis: Data from a multicenter 24 weeks prospective study
by: Giuseppe Germanò, et al.
Published: (2022-09-01)

Effects of tofacitinib therapy on arginine and methionine metabolites in association with vascular pathophysiology in rheumatoid arthritis: A metabolomic approach
by: Boglárka Soós, et al.
Published: (2022-11-01)

Atypical presentation of Pneumocystis jirovecii pneumonia in a patient with rheumatoid arthritis treated with tofacitinib: a case presentation
by: Ian F. J. Pirker, et al.
Published: (2018-11-01)

The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study
by: Claudia Di Muzio, et al.
Published: (2024-01-01)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
by: Jürgen Wollenhaupt, et al.
Published: (2019-04-01)

Real-World Comparative Effectiveness of Tofacitinib and Tumor Necrosis Factor Inhibitors as Monotherapy and Combination Therapy for Treatment of Rheumatoid Arthritis
by: George W. Reed, et al.
Published: (2019-11-01)

Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
by: Gustavo Citera, et al.
Published: (2023-11-01)

Case report: JAKi and TNFi dual therapy is a potential treatment strategy for difficult-to-treat rheumatoid arthritis
by: Jing-Wen Chen, et al.
Published: (2022-12-01)

The effect of tofacitinib on function and quality of life indicators in patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs in real clinical practice: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2017-03-01)

Efficacy and safety of Tofacitinib in patients with active rheumatoid arthritis resistant to conventional therapy: Preliminary results of an open-label clinical trial
by: E. L. Luchikhina, et al.
Published: (2016-06-01)

A new trend in pathogenetic treatment of rheumatoid arthritis: tofacitinib, the first inhibitor of Janus kinase
by: Dmitry Evgenyevich Karateev
Published: (2014-03-01)